Search Results for: ACT 1 test
BioReference to Provide Diagnostic Test Services and Assist with Patient-Centered Data Analytics ELMWOOD PARK, NJ. (August 1, 2019) – BioReference Laboratories, Inc., one of the largest clinical laboratories in the United States, today announced it has been selected by The IPA Association of America (TIPAAA) as its preferred provider of laboratory services and to assist with data […]
BioReference to also assist with Patient-Centered Data Analytics to SOMOS Providers SOMOS, New York City’s Largest Multi-Cultural Physician-Led Network Selects BioReference as Preferred Provider for Diagnostic Testing MIAMI, FL., July 01, 2019 (GLOBE NEWSWIRE) — BioReference Laboratories, Inc., an OPKO Health (NASDAQ: OPK) company and one of the largest clinical laboratories in the United States, has been selected […]
Complimentary PSA Testing Provided to Participants of Annual Golf Tournament ELMWOOD PARK, June 7 – BioReference Laboratories, Inc., along with its specialty oncology and urology division, GenPath, announce today their support of Man Cave Health’s upcoming charity golf tournament for Men’s Health Month, observed annually in the United States during the month of June. The event will […]
ELMWOOD PARK, NJ, April 22, 2019 – BioReference Laboratories Inc., an OPKO Health Company (NYSE:OPK), is pleased to announce it will gain preferred laboratory network provider status for UnitedHealthcare. The contract includes BioReference’s subsidiary GeneDx, a full service genetics laboratory. Learn about the UnitedHealthcare Preferred Lab Network here. “At BioReference we are committed to making […]
ELMWOOD PARK, Jan. 28, 2019 – BioReference Laboratories Inc., an OPKO Health Company, today announced that they will offer flexible payment arrangements for federal employees affected by the government shutdown. “We recognize the challenging financial position that federal government employees have faced throughout the shutdown,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “While the […]




